AMT-116 in Combination With AK112 in Patients With Lung Cancer
A phase 1/2 trial of Ivonescimab in non-small-cell lung cancer and small-cell lung cancer, run by Multitude Therapeutics Inc., now recruiting.
Overview
AMT-116 in Combination With AK112 in Patients With Lung Cancer is a phase 1/2 interventional study registered as NCT07590531 by Multitude Therapeutics Inc., with 118 participants planned, started 2026-06-29 and due to reach its primary completion in 2027-05-30. Interventions recorded: AMT-116, AK112. Conditions listed: Advanced Non-small Cell Lung Cancer (NSCLC). No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialAMT-116 in Patients with Solid Tumors
Shares AMT-116, Multitude Therapeutics.
- TrialA Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Small Cell Lung Cancer
Shares Ivonescimab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialIvonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer
Shares Ivonescimab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialClinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Shares Ivonescimab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialAK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer
Shares Ivonescimab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors
Shares Ivonescimab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialPhase III Study of AK112 for NSCLC Patients
Shares Ivonescimab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialAK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC
Shares Ivonescimab, Small-cell lung cancer, Non-small-cell lung cancer.